Cargando…
EGFR突变NSCLC患者TKIs耐药后ICIs治疗进展
The follow-up treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation after drug resistance to EGFR-tyrosine kinase inhibitors (TKIs) have become a hotspot and difficulty at present. Immune checkpoint inhibitors (ICIs) therapy is a...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411951/ https://www.ncbi.nlm.nih.gov/pubmed/36002197 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.37 |